natgillin/translations-raw huggingface dataset:
Use of AADs (antiarrhythmic drugs) prior to or after vernakalant Vernakalant cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
Uporaba antiaritmikov pred vernakalantom ali po njem Zaradi pomanjkanja podatkov vernakalant ne moremo priporočiti bolnikom, ki so 4-24 ur pred vernakalantom prejeli intravenske antiaritmike (skupine I in III).
• Continue to monitor the patient for 2 hrs after the start of infusion and until clinical and ECG parameters have stabilised.
• Bolnike je treba še naprej nadzorovati 2 uri po začetku infundiranja ter dokler se klinični in
Cases of serious hypotension have been reported during and immediately following vernakalant infusion.
Med infundiranjem in takoj po infundiranju vernakalanta so poročali o primerih resne hipotenzije.
Patients should be frequently monitored for the duration of the infusion and for at least 15 minutes after the completion of the infusion for signs and symptoms of a sudden decrease in blood pressure or heart rate.
Pri bolniku je treba med infundiranjem in še vsaj 15 minut po zaključku infundiranja pogosto preveriti, če ima znake in simptome nenadnega znižanja krvnega tlaka ali srčne frekvence.
• certain heart diseases involving the heart muscle, lining that surrounds the heart and a severe narrowing of the heart valves
srčno popuščanje določene bolezni srca, ki prizadenejo srčno mišico, srčno ovojnico in hudo zoženje srčnih zaklopk bolezen srčnih zaklopk težave z jetri če jemljete druga zdravila za urejanje srčnega ritma
There is limited experience with vernakalant in patients with pacemakers.
Izkušenj z vernakalantom pri bolnikih s srčnim spodbujevalnikom je malo.
Vernakalant was shown to provide relief of atrial fibrillation symptoms consistent with conversion to sinus rhythm.
†Cochran-Mantel-Haenszlov test Ugotovljeno je bilo, da vernakalant olajša simptome atrijske fibrilacije, skladno s prehodom v sinusni ritem.
• pale skin
• suha usta • bleda koža
Prior to administration the prescriber is asked to determine eligibility of the patient through use of the supplied checklist.
zdravilu je priložen kontrolni seznam, s katerim mora predpisovalec pred uporabo zdravila preveriti, če je bolnik primeren za zdravljenje s tem zdravilom.
Uncommon: Dyspnoea; throat irritation; oropharyngeal pain; nasal congestion; suffocation feeling; choking sensation; rhinorrhoea Gastrointestinal disorders Common: Nausea; paraesthesia oral; vomiting Uncommon: Dry mouth; diarrhoea; hypoaesthesia oral; defecation urgency
Pogosti: navzea, parestezija v ustih, bruhanje Občasni: suha usta, driska, hipestezija v ustih, nuja po defekaciji Bolezni kože in podkožja Pogosti: srbenje, hiperhidroza Občasni: generalizirano srbenje, hladen znoj
One patient who received 3 mg/kg of vernakalant over 5 minutes (instead of the recommended 10 minutes) developed haemodynamically stable wide complex tachycardia which resolved without sequelae.
Enemu bolniku, ki je prejel 3 mg/kg vernakalanta v 5 minutah (namesto v priporočenih 10 minutah),
If you think that you may have been given too much BRINAVESS, tell your doctor straight away.
Če ste dobili večji odmerek zdravila BRINAVESS, kot bi smeli Če menite, da ste dobili preveč zdravila BRINAVESS, to nemudoma povejte zdravniku.
How to store BRINAVESS Contents of the pack and other information
Vsebina pakiranja in dodatne informacije
Glucuronidation and renal excretion are the main mechanisms of elimination in CYP2D6 poor metabolisers.
Pri slabih metabolizatorjih s CYP2D6 sta glavna mehanizma odstranjevanja glukuronidacija in izločanje skozi ledvice.
In adults it is used if you have a fast, irregular heart beat called atrial fibrillation which has started recently, less than or equivalent to 7 days, for non-surgery patients and less than or equivalent to 3 days for post-cardiac surgery patients.
ki se vam je pojavil pred kratkim, pred 7 dnevi ali manj, za nekirurške bolnike in 3 dnevi ali manj za bolnike po kardiokirurškem posegu.
• if you take certain other intravenous medicines (antiarrhythmics Class I and III) used to normalize an abnormal heart rhythm, 4 hours before BRINAVESS is to be used
• če ste v 4 urah pred tem, ko naj bi vzeli zdravilo BRINAVESS, vzeli določena druga intravenska zdravila (antiaritmike skupine I in III), ki se uporabljajo za ureditev nepravilnega srčnega ritma.
Acute vernakalant pharmacokinetics is not significantly influenced by gender, history of congestive heart failure, renal impairment, or concomitant administration of beta blockers and other medications, including warfarin, metoprolol, furosemide and digoxin.
Spol, anamneza kongestivnega srčnega popuščanja, okvara ledvic ali sočasno prejemanje blokatorjev beta in drugih zdravil (vključno z varfarinom, metoprololom, furosemidom in digoksinom) ne vpliva pomembno na akutno farmakokinetiko vernakalanta.
• Use of intravenous rhythm control antiarrhythmics (class I and class III) within 4 hours prior to, as well as in the first 4 hours after, BRINAVESS administration.
• Uporaba intravenskih antiaritmikov za kontrolo srčnega ritma (skupine I in III) v 4 urah pred uporabo in prve 4 ure po uporabi vernakalanta.
Vernakalant should be used with caution in patients on oral AADs (class I and III), due to limited experience.
Vernakalant je treba pri bolnikih, ki prejemajo peroralne antiaritmike (skupine I in III), zaradi pomanjkanja izkušenj uporabljati previdno.
Common: Paraesthesia; dizziness
Zelo pogosti: disgevzija Pogosti: parestezije, omotica
-For non-surgery patients: atrial fibrillation ≤ 7 days duration -For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
Hitra konverzija nedavno nastale atrijske fibrilacije v sinusni ritem pri odraslih - za nekirurške bolnike: atrijska fibrilacija, ki traja ≤ 7 dni - za bolnike po kardiokirurškem posegu: atrijska fibrilacija, ki traja ≤ 3 dni
This medicinal product contains 80 mg sodium per 500 mg vial, equivalent to 4 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.
To zdravilo vsebuje 80 mg natrija v eni viali s 500 mg, kar je enako 4 % največjega dnevnega vnosa natrija za odrasle osebe, ki ga priporoča WHO in znaša 2 g. 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Do not use BRINAVESS if you take certain other intravenous medicines (antiarrhythmics Class I and III) used to normalize an abnormal heart rhythm, 4 hours before BRINAVESS is to be used.
Zdravila BRINAVESS ne jemljite, če ste 4 ure pred uporabo zdravila BRINAVESS uporabili nekatera druga zdravila za urejanje nenormalnega srčnega ritma (intravenske antiaritmike skupine I in III).
Patients with a history of CHF showed a higher incidence of ventricular arrhythmia in the first two hours post dose (6.4% for vernakalant compared to 1.6% in placebo).
Pri bolnikih z anamnezo kongestivnega srčnega popuščanja je bila v prvih dveh urah po odmerku pojavnost prekatnih motenj srčnega ritma večja (6,4 % z vernakalantom in 1,6 % s placebom).
Each 25 ml vial contains 500 mg of vernakalant hydrochloride equivalent to 452.5 mg of vernakalant.
Ena 25 ml viala vsebuje 500 mg vernakalantijevega klorida, kar ustreza 452,5 mg vernakalanta.
Name and address of the manufacturer responsible for batch release
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij Geodis Logistics Netherlands B.V.
PARTICULARS TO APPEAR WITHIN THE OUTER PACKAGING (CARTON) PRE-INFUSION CHECK-LIST
PODATKI NA ZUNANJI OVOJNINI (ŠKATLA) KONTROLNI SEZNAM PRED INFUNDIRANJEM ZDRAVILA
Elderly (≥ 65 years): No dose adjustment necessary.
Starejši (≥ 65 let):
ACT I and ACT III studied the effect of vernakalant in the treatment of patients with sustained atrial fibrillation > 3 hours but not more than 45 days in duration.
Študiji ACT I in ACT III sta preučevali učinek vernakalanta pri bolnikih z obstojno atrijsko fibrilacijo,
• choking sensation
• občutek dušenja
If you get any side effects, talk to your doctor.
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
BRINAVESS 20 mg/ml concentrate for solution for infusion vernakalant hydrochloride
BRINAVESS 20 mg/ml koncentrat za raztopino za infundiranje vernakalantijev klorid
Vernakalant given by infusion is not expected to perpetrate meaningful drug interactions due to the rapid distribution and transient exposure, low protein binding, lack of inhibition of other CYP P450 enzymes tested (CYP3A4, 1A2, 2C9, 2C19 or 2E1) and lack of P-glycoprotein inhibition in a digoxin transport assay.
P450 (CYP3A4, 1A2, 2C9, 2C19 ali 2E1) in v preizkusu transporta digoksina ne zavre Pglikoproteina.
Each vial contains 500 mg vernakalant hydrochloride equivalent to 452.5 mg vernakalant.
Ena viala vsebuje 500 mg vernakalantijevega klorida, kar ustreza 452,5 mg vernakalanta.
Step 1: BRINAVESS vials should be visually inspected for particulate matter and discolouration before administration.
1. korak: Pred uporabo morate viale zdravila BRINAVESS pregledati in se prepričati, da ne vsebujejo delcev in da vsebina ni spremenila barve.
The osmolality of the medicinal product is controlled between the following range: 270-320 mOsmol/kg
bistra in brezbarvna do bledorumena raztopina s pH približno 5,5 Osmolalnost zdravila je kontrolirana v območju 270-320 mOsmol/kg.
This will be a slightly lower dose of 2 mg/kg, with a maximum calculated dose based upon 113 kg. Total doses of greater than 5 mg/kg should not be administered within 24 hours.
Ta odmerek bo nekoliko manjši, 2 mg/kg, z največjim izračunanim odmerkom za 113 kg.
BRINAVESS contains the active substance vernakalant hydrochloride.
Kaj je zdravilo BRINAVESS in za kaj ga uporabljamo Zdravilo BRINAVESS vsebuje učinkovino vernakalantijev klorid.
• BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
• Zdravila BRINAVESS zaradi pomanjkanja podatkov ne moremo priporočiti bolnikom, ki so 4-24 ur pred vernakalantom prejeli intravenski antiaritmik (skupine I in III).
Each ml of concentrate contains 20 mg vernakalant hydrochloride equivalent to 18.1 mg vernakalant.
En ml koncentrata vsebuje 20 mg vernakalantijevega klorida, kar ustreza 18,1 mg vernakalanta.
Direct-current cardioversion may be considered for patients who do not respond to therapy.
Za bolnike, ki se na zdravljenje ne odzovejo, pride v poštev kardioverzija z enosmernim tokom.
Sodium hydroxide (E524) (for pH-adjustment)
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi citronska kislina (E330) natrijev klorid voda za injekcije natrijev hidroksid (E524) (za uravnavanje pH)
In patients with uncorrected hypokalaemia (serum potassium of less than 3.5 mmol/l), potassium levels should be corrected prior to use of vernakalant.
Bolnikom z nekorigirano hipokaliemijo (koncentracija kalija v serumu manj kot
Common: Infusion site pain; feeling hot; infusion site paraesthesia Uncommon: Fatigue; infusion site irritation; infusion site hypersensitivity; infusion site pruritus; malaise
Občasni: utrujenost, draženje na mestu infundiranja, preobčutljivost na mestu infundiranja, srbenje na mestu infundiranja, splošno slabo počutje
There are no clinical data on repeat doses after the initial and second infusions.
Kliničnih podatkov o ponovni uporabi po začetni in drugi infuziji ni. Kot kaže, je koncentracija vernakalanta po 24 urah zanemarljiva.
Each vial contains 200 mg vernakalant hydrochloride equivalent to 181 mg vernakalant.
Ena viala vsebuje 200 mg vernakalantijevega klorida, kar ustreza 181 mg vernakalanta.
Each 10 ml vial contains 200 mg of vernakalant hydrochloride equivalent to 181 mg of vernakalant.
Ena 10 ml viala vsebuje 200 mg vernakalantijevega klorida, kar ustreza 181 mg vernakalanta.
Clinically significant adverse reactions observed in clinical trials included hypotension and ventricular arrhythmia.
Med klinično pomembnimi neželenimi učinki v kliničnih preskušanjih so bile hipotenzija in prekatne motnje srčnega ritma (glejte poglavji 4.4 Hipotenzija, Kongestivno srčno popuščanje).
The patient is required to be monitored for signs and symptoms of a sudden decrease in blood pressure or heart rate for the duration of the infusion and for at least 15 minutes after the completion of the infusion.
Bolnika je treba med infundiranjem ter še vsaj 15 minut po zaključku infundiranja nadzorovati glede znakov in simptomov nenadnega znižanja krvnega tlaka ali srčne frekvence.
These effects, seen within 24 hours of being given BRINAVESS, should pass quickly, however, if they do not you should consult your doctor.
• kihanje Ta neželena učinka, ki se opazita v 24 urah po dajanju zdravila BRINAVESS, naj bi minila hitro.
Please refer to the Summary of Product Characteristics and the educational material for additional information prior to the use of BRINAVESS
Pred uporabo zdravila BRINAVESS za dodatne informacije preberite Povzetek glavnih značilnosti tega zdravila in izobraževalno gradivo.
Do NOT give other IV antiarrhythmic medicines (class I and/or class III) for at least 4 hours after infusion of BRINAVESS.
Vsaj 4 ure po infuziji zdravila BRINAVESS NE smete dati drugih intravenskih antiaritmikov (skupine I in/ali III).
A pre-infusion checklist is provided with the medicinal product.
K zdravilu je priložen kontrolni seznam, s katerim mora predpisovalec pred uporabo zdravila preveriti,
Each vial of 200 mg vernakalant hydrochloride is equivalent to 181 mg vernakalant.
Ena viala z 200 mg vernakalantijevega klorida ustreza 181 mg vernakalanta.
Resumption or initiation of oral maintenance antiarrhythmic therapy can be considered starting 2 hours after vernakalant administration.
Ponoven začetek ali uvedba peroralnega vzdrževalnega antiaritmičnega zdravljenja pride v poštev
BRINAVESS is a concentrate for solution for infusion (sterile concentrate) which is clear and colourless to pale yellow.
Zdravilo BRINAVESS je bister, brezbarven do bledorumen koncentrat za raztopino za infundiranje (sterilen koncentrat).
Vernakalant given by infusion is not expected to perpetrate meaningful drug drug interactions due to the rapid distribution and transient exposure, low protein binding, lack of inhibition of other CYP P450 enzymes tested (CYP3A4, 1A2, 2C9, 2C19 or 2E1) and lack of P-glycoprotein inhibition in a digoxin transport assay.
Ni pričakovati, da bi infundirani vernakalant povzročil pomembna medsebojna delovanja zdravil, ker se hitro porazdeli in je izpostavljenost prehodna, vezava na beljakovine majhna, ne zavira drugih testiranih encimov CYP
Each vial of 500 mg of vernakalant hydrochloride is equivalent to 452.5 mg of vernakalant.
Ena viala s 500 mg vernakalantijevega klorida ustreza 452,5 mg vernakalanta.
No dose adjustment of vernakalant is required on the basis of CYP2D6 metaboliser status, or when vernakalant is administered concurrently with 2D6 inhibitors.
CYP2D6, ali če je vernakalant uporabljen sočasno z zaviralci 2D6.
STATEMENT OF ACTIVE SUBSTANCE
NAVEDBA ZDRAVILNE UČINKOVINE
Package leaflet: Information for the user BRINAVESS 20 mg/ml concentrate for solution for infusion vernakalant hydrochloride
Navodilo za uporabo BRINAVESS 20 mg/ml koncentrat za raztopino za infundiranje vernakalantijev klorid
• generalised itching
• splošno srbenje • utrujenost
• fatigue
Correvop
• Use of intravenous rhythm control antiarrhythmics (class I and class III) within 4 hours prior to,
• Intravenskih antiaritmikov za kontrolo srčnega ritma se v prvih 4 urah po uporabi zdravila
The safety of vernakalant has been evaluated in clinical studies involving 1,148 subjects (patients and healthy volunteers) who received treatment with it. Based on data from 1,018 patients in eight phase 2 and phase 3 trials, the most commonly reported adverse reactions (> 5 %) seen in the first 24 hours after receiving vernakalant were dysgeusia (taste disturbance) (17.9 %), sneezing (12.5 %), and paraesthesia (6.9 %).
3. faze so bili najpogosteje poročani neželeni učinki (> 5 %), ki so se pojavili v prvih 24 urah po uporabi vernakalanta, disgevzija (motnja okušanja) (7,9 %), kihanje (12,5 %) in parestezije (6,9 %).
If conversion to sinus rhythm did not occur with the initial infusion or within the 15 minute observation period, administer a 2 mg/kg second infusion over 10 minutes.
Če bolnik po začetni infuziji ali v 15 minutnem obdobju spremljanja ne preide v sinusni ritem,
Efficacy in patients who developed atrial fibrillation post cardiac surgery (ACT II) Efficacy was studied in patients with atrial fibrillation after cardiac surgery in ACT II, a phase 3, double-blind, placebo-controlled, parallel group study (ACT II) in 150 patients with sustained atrial fibrillation (3 hours to 72 hours duration) that occurred between 24 hours and 7 days post coronary artery bypass graft and/or valvular surgery.
Učinkovitost pri bolnikih, ki se jim je atrijska fibrilacija pojavila po kardiokirurškem posegu (ACT II) Učinkovitost pri bolnikih z atrijsko fibrilacijo po kardiokirurškem posegu so raziskali v študiji ACT II.
• coughing, sore nose
• kašelj, vnet nos • prekomerno znojenje, srbenje
Common: Cough; nasal discomfort
Zelo pogosti: kihanje Pogosti: kašelj, nelagodje v nosu
• the electrical activity of your heart (uncommon)
(občasni), kratki premori med normalnim delovanjem srca (občasni))
This summary was last updated in January 2012.
Ta povzetek je bil nazadnje posodobljen januarja 2012.
In rare cases, particularly in older or in sensitive dogs, these effects may become very serious.
V redkih primerih, zlasti pri starejših ali občutljivih psih, lahko postanejo ti učinki zelo resni.
Zubrin should not be used in people.
Zdravilo Zubrin se ne sme uporabljati za ljudi.
If the lyophilisate disintegrates prematurely in your hands, wash your hands thoroughly.
Če se liofilizat prezgodaj raztopi v vaših rokah, si roke temeljito umijte.
The European Commission granted a marketing authorisation valid throughout the European Union, for Zubrin on 13 March 2001.
Evropska Komisija je dovoljenje za promet z zdravilom Zubrin, veljavno po vsej Evropski uniji, odobrila dne 13. marca 2001.
Occasionally, loss of hair or red patches on the skin might occurr.
Občasno lahko pride do izpadanja dlake ali pojava rdečih lis na koži.
In these clinical studies, the animal owners gave Zubrin to their dogs, once daily at a dose of 10 mg per kg dog's bodyweight with or without food.
V teh kliničnih raziskavah so lastniki živali dajali Zubrin psom enkrat dnevno v odmerku 10 mg na kg telesne mase psa z ali brez hrane.
Vomiting or diarrhoea has been observed in one out of 10 dogs.
Bruhanje ali drisko so opazili pri enem izmed 10 psov.
Zubrin has been studied in laboratory animals, as well as in dogs that were treated in various veterinary practices/clinics in the USA and in a number of countries in Europe (“clinical studies”).
Zdravilo Zubrin je bilo preučeno na laboratorijskih živalih in na psih, ki so bili zdravljeni v različnih veterinarskih ambulantah/klinikah v ZDA in številnih državah v Evropi („klinične raziskave“).
Also, before you start using Zubrin, inform the veterinarian if your dog receives any other medication since some medicines might influence each other's effectiveness.
Ravno tako je treba pred začetkom uporabe zdravila Zubrin veterinarja obvestiti, če pes prejema katerakoli druga zdravila, saj lahko nekatera zdravila vplivajo na učinkovitost drugih zdravil.
Information on the prescription status of this product may be found on the label of the carton.
Podatki o statusu predpisovanja tega zdravila so navedeni na škatli zdravila.
The best results were achieved when Zubrin was adminstered 1-2 hours after feeding.
Najboljše rezultate so dosegli z dajanjem zdravila Zubrin 1-2 uri po hranjenju.
Its purpose is to explain how the assessment done by the CVMP on the basis of the documentation provided led to the recommendations on the conditions of use.
Njegov namen je pojasniti, kako je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) na podlagi ocene predložene dokumentacije oblikoval priporočila glede uporabe zdravila.
However, since side effects might occur, any treatment exceeding 1 - 2 weeks should be under regular veterinary supervision.
Ker pa se lahko pojavijo neželeni učinki, mora biti vsako zdravljenje, ki je daljše od 1 do 2 tednov, pod rednim veterinarskim nadzorom.
Zubrin acts by blocking enzymes, cyclooxygenase-1 and cyclooxygenase-2.
Zdravilo Zubrin deluje z zaviranjem encimov ciklooksigenaza-1 in ciklooksigenaza-2.
Zubrin should be placed directly into the dog's mouth and you should try to keep the mouth of the dog closed for a short while.
Zdravilo Zubrin morate položiti neposredno v gobec psa, nato pa poskusite gobec psa za kratek čas zadržati zaprtega.
When such undesirable effects are seen in the dog, you should discontinue giving Zubrin to your dog.
Če se pri psu pojavijo takšni neželeni učinki, je treba dajanje zdravila Zubrin prekiniti.
Zubrin is given to the dog once a day within 1-2 hours after feeding until the dog gets better.
Zdravilo Zubrin se daje psom enkrat dnevno 1-2 uri po hranjenju, dokler se stanje ne izboljša.
Zubrin contains tepoxalin, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Zdravilo Zubrin vsebuje tepoksalin, ki spada v skupino zdravil z imenom nesteroidna protivnetna zdravila (NSPVZ).
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Zubrin are greater than any risks when treating inflammation or pain in muscles or joints in dogs and they recommended that Zubrin should be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristni učinki zdravila Zubrin pri zdravljenju vnetja ali bolečin v mišicah ali sklepih pri psih večji od vseh tveganj, in priporoča odobritev dovoljenja za promet z zdravilom Zubrin.
Why has Zubrin been approved?
Zakaj je bilo zdravilo Zubrin odobreno?
Therefore, you should make sure to administer the medicine with dry hands.
Zato zdravilo vedno dajajte s suhimi rokami.
Zubrin was as effective as other medicines of the same class and showed significant improvement in dogs with muscle or joint disease.
Zdravilo Zubrin je bilo učinkovito enako kot druga zdravila iz iste skupine in je pokazalo statistično značilno izboljšanje stanja pri psih z boleznimi mišic ali sklepov.
When these enzymes are blocked, less prostaglandin is produced.
Ko sta ta dva encima zavrta, pride do zmanjšane tvorbe prostaglandinov.
Zubrin is used in dogs to reduce inflammation and relief of pain caused by acute and chronic musculoskeletal disorders.
Zdravilo Zubrin se uporablja za zmanjšanje vnetja in bolečine, ki jih povzročajo akutna in kronična mišičnoskeletna obolenja.
Zubrin is an oral lyophilisate, i.e. a kind of tablet that will quickly disintegrate upon contact with moisture e.g. when placed on your dog's tongue.
Zdravilo Zubrin je oralni liofilizat, t. j. vrsta tablet, ki se hitro razgradijo ob stiku z vlago, npr. ko tableto položite na jezik psa.
Zubrin has a special pharmaceutical form (lyophilisate) that will quickly dissolve upon contact with moisture and might get very slippery or sticky when kept in your fingers.
Zdravilo Zubrin je v posebni farmacevtski obliki (liofilizat), ki se hitro raztopi pri stiku z vlago in lahko postane zelo spolzko ali lepljivo, če ga držite med prsti.
The side effects of Zubrin are those seen with other NSAIDs, such as vomiting, soft faeces or diarrhoea, blood in faeces, reduced appetite and tiredness.
Neželeni učinki zdravila Zubrin so enaki kot pri drugih nesteroidnih protivnetnih zdravilih, in sicer vključujejo bruhanje, mehko blato ali drisko, kri v blatu, zmanjšan apetit in utrujenost.
However, if a number of tablets are accidentially consumed by a person, the advice of a doctor should be sought immediately.
Če pride do nenamernega zaužitja več tablet pri človeku, se nemudoma posvetujte z zdravnikom.
What is Zubrin used for?
Za kaj se zdravilo Zubrin uporablja?
What are the side effects of Zubrin?
Kakšni so neželeni učinki zdravila Zubrin?
As the prostaglandins are substances that trigger inflammation, tepoxalin reduces the inflammation and the swelling of muscles or joints and the pain associated with this.
Ker prostaglandini sprožajo vnetje, tepoksalin zmanjša vnetje in otekanje mišic ali sklepov ter bolečine,